A phase II trial with rosiglitazone in liposarcoma patients

Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this...

Descripción completa

Detalles Bibliográficos
Autores principales: Debrock, G, Vanhentenrijk, V, Sciot, R, Debiec-Rychter, M, Oyen, R, Van Oosterom, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394353/
https://www.ncbi.nlm.nih.gov/pubmed/14562008
http://dx.doi.org/10.1038/sj.bjc.6601306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394353/
https://www.ncbi.nlm.nih.gov/pubmed/14562008
http://dx.doi.org/10.1038/sj.bjc.6601306

Ejemplares similares